Search Results - Saoud, K.M.

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Vapor phase synthesis and characterization of bimetallic alloy and supported nanoparticle catalysts

    Vapor phase synthesis and characterization of bimetallic alloy and supported nanoparticle catalysts by Abdelsayed, V., Saoud, K.M., El-Shall, M. Samy

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    1-D nanostructures grown on the Si(5 5 12) surface

    1-D nanostructures grown on the Si(5 5 12) surface by Baski, A.A., Saoud, K.M., Jones, K.M.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    STM studies of 1-D noble metal growth on silicon

    STM studies of 1-D noble metal growth on silicon by Baski, A.A, Jones, K.M, Saoud, K.M

    Published in Ultramicroscopy
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Arthrodiastasis in treatment of Legg–Calvè–Perthes' disease

    Arthrodiastasis in treatment of Legg–Calvè–Perthes' disease by Shata, O, Saoud, A.M.F, Emara, K.M, Abdelghafar, K

    Published in Bone (New York, N.Y.)
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    G.O.24

    G.O.24 by Mendell, J.R, Rodino-Klapac, L, Sahenk, Z, Roush, K, Bird, L, Lowes, L.P, Alfano, L, Gomez, A.M, Lewis, S, Malik, V, Shontz, K, Flanigan, K.M, Shilling, C, Sazani, P, Saoud, J, Duda, P, Kaye, E

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    PP09.16 – 2691: Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): 3.2 year update on six-minute walk test (6MWT), pulmonary function testing (PFT), and safety

    PP09.16 – 2691: Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): 3.2 year update on six-minute walk test (6MWT), p... by Kaye, E.M, Mendell, J.R, Rodino-Klapac, L, Sahenk, Z, Roush, K, Lowes, L.P, Alfano, L, Gomez, A.M, Malik, V, Flanigan, K.M, Shilling, C, Duda, P, Saoud, J

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    P.11.20 Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD

    P.11.20 Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD by Mendell, J.R, Rodino-Klapac, L, Sahenk, Z, Roush, K, Bird, L, Lowes, L.P, Alfano, L, Gomez, A.M, Lewis, S, Malik, V, Shontz, K, Flanigan, K.M, Kean, J.R, Allen, H.D, Shilling, C, Sazani, P, Saoud, J, Kaye, E.M

    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    G.O.24: Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute Walk Test (6MWT) and Safety

    G.O.24: Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute Walk Test (6MWT) and Safety by Mendell, J.R., Rodino-Klapac, L., Sahenk, Z., Roush, K., Bird, L., Lowes, L.P., Alfano, L., Gomez, A.M., Lewis, S., Malik, V., Shontz, K., Flanigan, K.M., Shilling, C., Sazani, P., Saoud, J., Duda, P., Kaye, E.

    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    P.11.20 Results at 2years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD

    P.11.20 Results at 2years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD by Mendell, J.R., Rodino-Klapac, L., Sahenk, Z., Roush, K., Bird, L., Lowes, L.P., Alfano, L., Gomez, A.M., Lewis, S., Malik, V., Shontz, K., Flanigan, K.M., Kean, J.R., Allen, H.D., Shilling, C., Sazani, P., Saoud, J., Kaye, E.M.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: